Rojas MRL, Martínez MCL

Language: Spanish
References: 14
Page: 73-80
PDF size: 241.03 Kb.

ABSTRACT

Drug-induced catalepsy in rodents is an experimental model commonly used to study extrapyramidalism. The technique has not been standardized, and the methodologies used are difficult to conduct and do not always facilitate the evaluation of results. Reference has also been made to various factors which might lead to pseudocatalepsy or to a false positive response. The objective of this study was to develop a simple, reliable technique in which pseudocatalepsy would not be observed, and verify the viability of its application. A description is presented of a procedure using mice in a handmade device and the results obtained after modifying the variables posture of the animal, time to make the observation, and number of observations for a given animal. Haloperidol was used as reference drug. It was concluded that the technique proposed is of easy application and yields consistent results, without any evidence of pseudocatalepsy in the sample used.

REFERENCES

1. Vera F, Navarro JF, Manzaneque JM. El modelo animal de catalepsia en psico-farmacología. Iberpsicologia. 1997:2(2).

2. Katzung BG, Masters SB, Trevor AJ, editors. Basic and Clinical Pharmacology. Cap. 29. Antipsychotic agents and lithium. 11a ed. New York: Access Medicine from McGraw-Hill; 2009.

3. Princep M. Investigación y desarrollo de abaperidona, un nuevo antipsicótico 5-HT2a / D2 y alfa 1 adrenérgico. Modelos in vitro e in vivo predictivos de eficacia y efectos adversos. Tesis de Doctorado. Universidad de Barcelona, 2004;28,58. [citado 8 de junio 2011]. Disponible en: http://dialnet.unirioja.es/servlet/tesis?codigo=3380&info=resumen&modo=popup

4. Trevizol F, Benvegnu DM, Barcelos RC, Pase CS, Segat HJ, Dias VT, et al. Comparative study between two animal models of extrapyramidal movement disorders: Prevention and reversion by pecan nut shell aqueous extract. Behav Brain Res. 2011;221:13-8.

5. Fink-Jensen A, Schmidt LS, Dencker D, Schulein C, Wess J, Wortwein G, et al. Antipsychotic-induced catalepsy is attenuated in mice lacking the M4 muscarinic acetylcholine receptor. Eur J Pharmacol. 2011;656:39-44.

6. Sanberg PR, Bunsey MD, Giordano M, Norman AB. The catalepsy test: its ups and downs. Behav Neurosci. 1988;102:748-59.

7. Vogel HG, Vogel WH, editors. Drug Discovery and Evaluation. Pharmacological Assays. Berlin: Springer, 1996. p. E:5.2.4.

8. Antelman SM, Caggiula AR, Kocan D, Knopf S, Meyer D, Edwards DJ, et al. One experience with `lower' or `higher' intensity stressors, respectively enhances or diminishes responsiveness to haloperidol weeks later: implications for understanding drug variability. Brain Res. 1991;566:276-83.

9. Perrault GH, Depoortere R, Morel E, Sanger DJ, Scatton B. Psychopharmacological profile of amisulpride: An antipsychotic drug with presynaptic D2/D3 dopamine receptor antagonist activity and limbic selectivity. J Pharmacol Exp Ther. 1997;280:73-82.

10. Kirschbaum KM, Hiemke C, Schmitt U. Rotarod impairment: catalepsy-like screening test for antipsychotic side effects. Int J Neurosci. 2009;119:1509-22.

11. Natesan S, Reckless GE, Barlow KBL, Nobrega JN, Kapur S. Partial agonists in schizophrenia - why some work and other do not; insights from preclinical animal models. Int J Neuropsychopharmacol. 2011;14(9):1165-78.

12. Wadenberg MLG, Fjällström AK, Federley M, Persson P, Stenqvist P. Effect of adjunct galantamine to risperidone, or haloperidol, in animal models of antipsychotic activity and extrapyramidal side-effects liability: involvement of the cholinergic muscarinic receptor. Int J Neuropsychopharmacol. 2011;14:644-54.

13. Rojas R, Pérez A, del Calvo O. Cálculo del índice terapéutico de una droga. Rev Cub Invest Bioméd. 1993;12:125-29.

14. Navarro JF, Muñoz AL, Rivas T, Miñarro J, Simon VM. Efectos del haloperidol sobre la catalepsia en ratones machos. Psicothema. 1992;4:369-377.